Shots:
- The P-lll RUXCOVID study involves assessing Ruxolitinib (5mg, bid) + SoC therapy vs PBO + SoC therapy in 432 patients aged ≥12 yrs. in a ratio (2:1) hospitalized for COVID-19 and not intubated or receiving ICU care prior to randomization
- The study did not meet its 1EPS of reducing the number of hospitalized COVID-19 patients who experienced severe complications @29days (death, mechanical ventilation or ICU care i.e. (12% vs 11.8%). The trial did not show benefits among 2EPs and exploratory endpoints including mortality rate @Day29 and time to recovery
- Ruxolitinib is an oral JAK 1 and JAK 2 tyrosine kinases inhibitor and is approved under the name Jakavi in EU and other countries for PV & MF
Click here to read full press release/ article | Ref: Novartis | Image: Financial Times
The post Novartis’ Ruxolitinib Fails to Meet its Primary Endpoint in P-lll RUXCOVID Study for COVID-19 first appeared on PharmaShots.
